

Dow P Hurst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11616735/publications.pdf>

Version: 2024-02-01

59
papers

3,068
citations

201385

27
h-index

155451

55
g-index

59
all docs

59
docs citations

59
times ranked

3356
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Targets of the Phytocannabinoids: A Complex Picture. <i>Progress in the Chemistry of Organic Natural Products</i> , 2017, 103, 103-131.	0.8	292
2	Pregnenolone Can Protect the Brain from Cannabis Intoxication. <i>Science</i> , 2014, 343, 94-98.	6.0	247
3	Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 89-112.	1.4	240
4	An Aromatic Microdomain at the Cannabinoid CB1 Receptor Constitutes an Agonist/Inverse Agonist Binding Region. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5139-5152.	2.9	189
5	A Lipid Pathway for Ligand Binding Is Necessary for a Cannabinoid G Protein-coupled Receptor. <i>Journal of Biological Chemistry</i> , 2010, 285, 17954-17964.	1.6	187
6	N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) Interaction with LYS 3.28(192) Is Crucial for Its Inverse Agonism at the Cannabinoid CB1 Receptor. <i>Molecular Pharmacology</i> , 2002, 62, 1274-1287.	1.0	170
7	Structural Mimicry in Class A G Protein-coupled Receptor Rotamer Toggle Switches. <i>Journal of Biological Chemistry</i> , 2004, 279, 48024-48037.	1.6	142
8	3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 539-549.	1.4	139
9	Palmitoylation and membrane cholesterol stabilize μ -opioid receptor homodimerization and G protein coupling. <i>BMC Cell Biology</i> , 2012, 13, 6.	3.0	92
10	(-)-7-Isythiocyanato-11-hydroxy-1,1-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor. <i>Molecular Pharmacology</i> , 2005, 68, 1623-1635.	1.0	86
11	Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1 Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1 Transmembrane Helix 7. <i>Molecular Pharmacology</i> , 2007, 71, 1512-1524.	1.0	79
12	Exploration of Biologically Relevant Conformations of Anandamide, 2-Arachidonylglycerol, and Their Analogues Using Conformational Memories. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4861-4872.	2.9	71
13	Conformational Memories and the Endocannabinoid Binding Site at the Cannabinoid CB1 Receptor. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3649-3659.	2.9	67
14	A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. <i>Biochemical Pharmacology</i> , 2002, 63, 2121-2136.	2.0	63
15	Identification of the GPR55 Agonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands. <i>Biochemistry</i> , 2011, 50, 5633-5647.	1.2	62
16	The Bioactive Conformation of Aminoalkylindoles at the Cannabinoid CB1 and CB2 Receptors: Insights Gained from (E)- and (Z)-Naphthylidene Indenes. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 5177-5187.	2.9	60
17	Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands. <i>Biochemistry</i> , 2013, 52, 9456-9469.	1.2	59
18	Helix 8 Leu in the CB1 Cannabinoid Receptor Contributes to Selective Signal Transduction Mechanisms. <i>Journal of Biological Chemistry</i> , 2007, 282, 25100-25113.	1.6	54

#	ARTICLE	IF	CITATIONS
19	Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. <i>Journal of Neuroscience</i> , 2015, 35, 13975-13988.	1.7	50
20	CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1 <i>H</i>)-one-3-carboxamides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8777-8791.	2.9	46
21	Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation. <i>International Journal of Quantum Chemistry</i> , 2002, 88, 76-86.	1.0	44
22	Cysteine 2.59(89) in the Second Transmembrane Domain of Human CB2 Receptor Is Accessible within the Ligand Binding Crevice: Evidence for Possible CB2 Deviation from a Rhodopsin Template. <i>Molecular Pharmacology</i> , 2005, 68, 69-83.	1.0	43
23	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 542-568.	2.9	40
24	Endogenous lipid activated G protein-coupled receptors: Emerging structural features from crystallography and molecular dynamics simulations. <i>Chemistry and Physics of Lipids</i> , 2013, 169, 46-56.	1.5	36
25	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6753-6771.	2.9	34
26	Structural Basis of G Protein-coupled Receptor-Gi Protein Interaction. <i>Journal of Biological Chemistry</i> , 2014, 289, 20259-20272.	1.6	32
27	Therapeutic Exploitation of GPR18: Beyond the Cannabinoids?. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14216-14227.	2.9	31
28	Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. <i>ACS Chemical Neuroscience</i> , 2016, 7, 776-798.	1.7	30
29	A Closer Look at Anandamide Interaction With TRPV1. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 144.	1.6	29
30	Chromenopyrazoles: Non-psychoactive and Selective CB ₁ Cannabinoid Agonists with Peripheral Antinociceptive Properties. <i>ChemMedChem</i> , 2012, 7, 452-463.	1.6	27
31	Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1216-1221.	1.3	25
32	Residues Accessible in the Binding-Site Crevice of Transmembrane Helix 6 of the CB2 Cannabinoid Receptor. <i>Biochemistry</i> , 2008, 47, 13811-13821.	1.2	24
33	One for the Price of Two Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors?. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 353-363.	4.0	23
34	Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6993-6999.	1.4	21
35	Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor. <i>Biochemistry</i> , 2017, 56, 473-486.	1.2	21
36	Crucial Positively Charged Residues for Ligand Activation of the GPR35 Receptor. <i>Journal of Biological Chemistry</i> , 2014, 289, 3625-3638.	1.6	20

#	ARTICLE	IF	CITATIONS
37	The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB ₂ Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]pyrrolidine (SR144528). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6593-6612.	2.9	19
38	Global fold of human cannabinoid type 2 receptor probed by solid-state ¹³ C and ¹⁵ N MAS NMR and molecular dynamics simulations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2014, 82, 452-465.	1.5	19
39	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8104-8126.	2.9	18
40	Methods for the Development of In Silico GPCR Models. <i>Methods in Enzymology</i> , 2017, 593, 405-448.	0.4	17
41	Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 593-608.	2.6	16
42	Conformational memories with variable bond angles. <i>Journal of Computational Chemistry</i> , 2008, 29, 741-752.	1.5	14
43	Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB ₂ receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 651-667.	2.6	14
44	Molecular Dynamics Methodologies for Probing Cannabinoid Ligand/Receptor Interaction. <i>Methods in Enzymology</i> , 2017, 593, 449-490.	0.4	11
45	Design, synthesis and biological evaluation of GPR55 agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4355-4367.	1.4	10
46	Towards A Molecular Understanding of The Cannabinoid Related Orphan Receptor GPR18: A Focus on Its Constitutive Activity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2300.	1.8	9
47	TRPV1 Activation by Anandamide via a Unique Lipid Pathway. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5742-5746.	2.5	7
48	Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1827-1830.	1.0	6
49	GPR6 Structural Insights: Homology Model Construction and Docking Studies. <i>Molecules</i> , 2020, 25, 725.	1.7	6
50	A dual substrate kinetic model for cytochrome P450BM3-F87G catalysis: simultaneous binding of long chain aldehydes and 4-fluorophenol. <i>Biotechnology Letters</i> , 2017, 39, 311-321.	1.1	5
51	The Nucleotide-Free State of the Cannabinoid CB ₂ /Gi Complex. <i>Cell</i> , 2020, 180, 603-604.	13.5	5
52	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5475-5482.	1.4	4
53	Structure-activity relationships of benzothiazole GPR35 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 612-615.	1.0	4
54	The NPXXY Motif Regulates β -Arrestin Recruitment by the CB ₁ Cannabinoid Receptor. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 731-748.	1.5	4

#	ARTICLE	IF	CITATIONS
55	(4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl)Methanone Hydrochloride (LDK1229): A New Cannabinoid CB1 Receptor Inverse Agonist from the Class of Benzhydryl Piperazine Analogs. <i>Molecular Pharmacology</i> , 2015, 87, 197-206.	1.0	3
56	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands. <i>ChemMedChem</i> , 2018, 13, 1102-1114.	1.6	1
57	Structural Insights from Recent CB1 X-Ray Crystal Structures. , 2019, , .		1
58	Models of Cannabinoid Inverse Agonism, Neutral Antagonism, and Agonism: Tools for Rational Drug Design. , 2009, , 235-278.		0
59	Inside Back Cover: Chromenopyrazoles: Non-psychoactive and Selective CB1 Cannabinoid Agonists with Peripheral Antinociceptive Properties (<i>ChemMedChem</i> 3/2012). <i>ChemMedChem</i> , 2012, 7, 536-536.	1.6	0